—
C+
C+ The full Closelook — membership. Open the C+ overview

Sarepta Therapeutics Inc (SRPT) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Sarepta Therapeutics Inc

SRPT in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Sarepta develops RNA-targeted and gene therapies for rare diseases, focused mainly on Duchenne muscular dystrophy and related muscle disorders. Its approved drugs, including Exondys 51, Vyondys 53 and Amondys 45, use exon-skipping to address specific dystrophin gene mutations, and Elevidys is an AAV gene therapy for the same condition. Earlier-stage programmes target other genetic muscle diseases through partnerships with Roche, Arrowhead and academic centres. It is headquartered in Cambridge, Massachusetts.
Where it sits in the stack
Sarepta carries no seat in Rubin or Halo, the diary's AI-linked indices, since its business sits outside the build-out chain entirely. Within our universe it belongs to the Healthcare sector, Biotechnology industry, tracked for its own therapeutic pipeline rather than any AI exposure.
Who it is priced against
Closelook has not assigned it a peer group in our data; the market often compares it with Alnylam Pharmaceuticals, another company built around RNA-based rare-disease treatments.
Why Closelook tracks it
It is a Russell 1000 constituent; it carries no Closelook score yet, as no module has been recorded, and the diary has not quoted it in any edition.
What the diary watches
The diary watches how Elevidys safety data and uptake evolve, since gene-therapy setbacks or approvals could reshape how the rest of the pipeline is read.

Sarepta Therapeutics Inc (SRPT) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for SRPT, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against SRPT on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Sarepta Therapeutics Inc (SRPT)?

Sarepta Therapeutics Inc trades as SRPT on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is SRPT in a Closelook index?

Not currently — Sarepta Therapeutics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does SRPT trade against its moving averages?

Recovery attempt under the 200-day: Trades +8.4% vs the 50-day and +4.4% vs the 200-day average, 20.6% below the 52-week high and +37% off the 52-week low; a death cross printed 72 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Sarepta Therapeutics Inc do?

Sarepta develops RNA-targeted and gene therapies for rare diseases, focused mainly on Duchenne muscular dystrophy and related muscle disorders. Its approved drugs, including Exondys 51, Vyondys 53 and Amondys 45, use exon-skipping to address specific dystrophin gene mutations, and Elevidys is an AAV gene therapy for the same condition. Earlier-stage programmes target other genetic muscle diseases through partnerships with Roche, Arrowhead and academic centres. Closelook has not assigned it a peer group in our data; the market often compares it with Alnylam Pharmaceuticals, another company built around RNA-based rare-disease treatments.

Where does Sarepta Therapeutics Inc sit in the AI build-out?

Sarepta carries no seat in Rubin or Halo, the diary's AI-linked indices, since its business sits outside the build-out chain entirely. Within our universe it belongs to the Healthcare sector, Biotechnology industry, tracked for its own therapeutic pipeline rather than any AI exposure. It is a Russell 1000 constituent; it carries no Closelook score yet, as no module has been recorded, and the diary has not quoted it in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for SRPT, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.